About CIBINQO1

​​​​​​​CIBINQO is a small molecule that works inside the cell to inhibit JAK1​​​​​​​
​​​​​​​JAK=Janus kinase.



​​​​​​​
A Convenient Oral Treatment1

​​​​​​​CIBINQO gives you the flexibility to tailor therapy to individual patients' needs and treatment goals
​​​​​​​


​​​​​​​
Start Guide

​​​​​​​​​​​​​​A quick reference guide that outlines what you need to know about starting appropriate patients on CIBINQO



​​​​​​​
DOWNLOAD START GUIDE
Safety Profile​​​​​​​​​​​​​​1
CIBINQO has been studied in moderate-to-severe atopic dermatitis in >2850 patients*

*Includes subjects from pivotal trials and additional phase 3 trials, one of which is ongoing.
TAKE IT ON with the POWER of 
CIBINQO.1
Explore the Efficacy Data   >
Real Patient Results


See before and after images of patients of varying skin tones



​​​​​​​
Request an eRep

​​​​​​​
Have a product question? Request a call from your product representative.


​​​​​​​
REQUEST A CALL
Reference:
​​​​​​​1. CIBINQO™ (abrocitinib) Full Prescribing Information. April 2021.

© 2021 Pfizer Pte Ltd. All rights reserved.


The information provided in this site is intended only for Healthcare Professionals in Singapore. The products discussed herein may have different product labelling in different countries. Pfizer Pte Ltd, Singapore is a subsidiary of Pfizer Inc, a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.